Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Helixmith Co. Ltd. currently manages 1 pending office action within its patent portfolio. This matter is being handled by 1 distinct examiner, indicating a highly concentrated prosecution focus at this stage. TRUONG, QUANGLONG N is identified as the busiest examiner for the company, responsible for the pending office action currently on record.
This concentration means that the outcome of the company's current pending prosecution depends entirely on the review of this individual. Practitioners should prepare for a singular interaction with the patent office, as there are no other examiners or pending matters to provide varied feedback. The strategy for this portfolio must be highly tailored to the specific requirements of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.8% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849175 | LIQUID FORMULATION PHARMACEUTICAL COMPOSITION COMPRISING PLASMID DNA | TRUONG, QUANGLONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849175 | LIQUID FORMULATION PHARMACEUTICAL COMPOSITION COMPRISING PLASMID DNA | TRUONG, QUANGLONG N | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849175 | LIQUID FORMULATION PHARMACEUTICAL COMPOSITION COMPRISING PLASMID DNA | TRUONG, QUANGLONG N | — | §101§102§103 | Non-Final OA | — | Pending | Sep 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial